Damm Robert, Zörkler Ingo, Rogits Bela, Hass Peter, Omari Jazan, Powerski Maciej, Kropf Sigrfried, Mohnike Konrad, Pech Maciej, Ricke Jens, Seidensticker Max
Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg.
Pawlow Poliklinik, Radiologische Gemeinschaftspraxis, Magdeburg.
J Contemp Brachytherapy. 2018 Dec;10(6):516-521. doi: 10.5114/jcb.2018.80626. Epub 2018 Dec 28.
Needle track seeding in the local treatment of hepatocellular carcinoma (HCC) is not yet evaluated for catheter-based high-dose-rate brachytherapy (HDR-BT), a novel local ablative technique.
We report a retrospective analysis of 100 patients treated on 233 HCC lesions by HDR-BT (using 588 catheters in total). No needle or catheter track irradiation was used. Minimum required follow-up with imaging was 6 months. In case of suspected needle track seeding (intra- and/or extrahepatic) in follow-up, image fusion of follow-up CT/MRI with 3D irradiation plan was used to verify the location of a new tumor deposit within the path of a brachytherapy catheter at the time of treatment.
We identified 9 needle track metastases, corresponding to a catheter-based risk of 1.5% for any location of occurrence. A total of 7 metastases were located within the liver (catheter-based risk, 1.2%), and 2 metastases were located extrahepatic (catheter-based risk, 0.3%). Eight out of 9 needle track metastases were successfully treated by further HDR-BT.
The risk for needle track seeding after interstitial HDR-BT of HCC is comparable to previous reports of percutaneous biopsies and radiofrequency ablation (RFA), especially in case of extrahepatic needle track metastases. To compensate for the risk of seeding, a track irradiation technique similar to track ablation in RFA should be implemented in clinical routine.
在肝细胞癌(HCC)局部治疗中,尚未对基于导管的高剂量率近距离放疗(HDR - BT)这一新型局部消融技术的针道种植情况进行评估。
我们报告了对100例接受HDR - BT治疗233个HCC病灶患者的回顾性分析(共使用588根导管)。未使用针道或导管道照射。影像学的最短随访时间为6个月。在随访中若怀疑有针道种植(肝内和/或肝外),则使用随访CT/MRI与三维照射计划的图像融合来核实治疗时近距离放疗导管路径内新肿瘤沉积的位置。
我们发现9例针道转移,对应基于导管的任何发生部位的风险为1.5%。共有7例转移位于肝内(基于导管的风险为1.2%),2例转移位于肝外(基于导管的风险为0.3%)。9例针道转移中的8例通过进一步的HDR - BT成功治疗。
HCC间质HDR - BT后针道种植的风险与先前经皮活检和射频消融(RFA)的报告相当,尤其是在肝外针道转移的情况下。为弥补种植风险,临床常规应采用类似于RFA中针道消融的针道照射技术。